ArticleGland surgery2026
Early outcomes of volume replacement using paste-type micronized acellular dermal matrix in oncoplastic breast-conserving surgery.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgical approaches in breast cancer have evolved to balance oncologic safety with cosmetic outcomes. Oncoplastic breast-conserving surgery (BCS) was developed to overcome the cosmetic limitations of conventional BCS and has been widely adopted in breast cancer treatment. Although the concept of oncoplastic BCS has been established for decades, breast and plastic surgeons continue to refine surgical techniques to achieve oncologic outcomes that are not inferior while improving aesthetic results. Therefore, this study aimed to evaluate the early postoperative outcomes and safety of oncoplastic BCS using paste-type micronized acellular dermal matrix (ADM) for volume replacement. Methods: This retrospective chart review included 167 female patients who underwent BCS at a single institution between February 2021 and May 2023. Patients were divided into two groups: BCS only (n=94) and BCS with volume replacement using paste-type micronized ADM (n=73). The decision to use ADM was made intraoperatively based on anticipated contour deformity after tumor excision, considering tumor location, defect size, and tissue characteristics, as well as patient preference. To adjust for baseline differences between groups, inverse probability of treatment weighting (IPTW) analysis was performed. Clinicopathologic characteristics, operative variables, and postoperative outcomes were analyzed. Results: Baseline clinicopathologic characteristics were initially imbalanced between the groups; however, after IPTW adjustment, variables including age and tumor characteristics were well balanced between the two groups. The mean operative time did not differ significantly between the BCS-only group and the ADM group (83.0 Conclusions: Oncoplastic BCS with volume replacement using paste-type micronized ADM appears to be a safe and technically feasible option with comparable early postoperative outcomes. Given the retrospective design and limited follow-up, further prospective studies with standardized cosmetic assessment and longer follow-up are required to clarify long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.